Korea Arlico Pharm Co.,Ltd. (KOSDAQ: 260660)
South Korea
· Delayed Price · Currency is KRW
3,405.00
-75.00 (-2.16%)
Nov 15, 2024, 9:00 AM KST
Korea Arlico Pharm Co.,Ltd. Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Operating Revenue | 178,827 | 187,155 | 167,737 | 140,157 | 124,809 | 115,793 | Upgrade
|
Other Revenue | - | - | - | -0 | 0 | - | Upgrade
|
Revenue | 178,827 | 187,155 | 167,737 | 140,157 | 124,809 | 115,793 | Upgrade
|
Revenue Growth (YoY) | -2.86% | 11.58% | 19.68% | 12.30% | 7.79% | 21.46% | Upgrade
|
Cost of Revenue | 81,947 | 77,038 | 60,871 | 52,672 | 45,134 | 42,421 | Upgrade
|
Gross Profit | 96,880 | 110,116 | 106,866 | 87,485 | 79,674 | 73,372 | Upgrade
|
Selling, General & Admin | 100,151 | 101,455 | 89,043 | 73,629 | 65,039 | 58,479 | Upgrade
|
Research & Development | 5,526 | 4,180 | 6,532 | 8,194 | 3,142 | 1,817 | Upgrade
|
Other Operating Expenses | 184.64 | 211.67 | 285.4 | 180.17 | 389.1 | 280.41 | Upgrade
|
Operating Expenses | 107,941 | 107,044 | 97,002 | 82,691 | 69,075 | 60,834 | Upgrade
|
Operating Income | -11,061 | 3,073 | 9,864 | 4,794 | 10,599 | 12,538 | Upgrade
|
Interest Expense | -1,587 | -1,587 | -968.39 | -276.95 | -639.09 | -982.66 | Upgrade
|
Interest & Investment Income | 435.17 | 435.17 | 518.13 | 167.72 | 361.15 | 440.69 | Upgrade
|
Currency Exchange Gain (Loss) | 36.71 | 36.71 | 141.57 | 138.03 | -74.76 | 58.36 | Upgrade
|
Other Non Operating Income (Expenses) | 1,648 | 1,319 | -1,019 | -213.08 | -344.92 | -226.48 | Upgrade
|
EBT Excluding Unusual Items | -10,528 | 3,276 | 8,536 | 4,610 | 9,902 | 11,828 | Upgrade
|
Gain (Loss) on Sale of Investments | 190.04 | 190.04 | 168.93 | 30.37 | 24.67 | 177.12 | Upgrade
|
Gain (Loss) on Sale of Assets | 9.08 | 9.08 | -313.88 | 964.68 | -198.54 | 72.13 | Upgrade
|
Pretax Income | -10,329 | 3,476 | 8,391 | 5,605 | 9,728 | 12,151 | Upgrade
|
Income Tax Expense | -1,464 | 414.67 | 356.96 | 675.18 | 1,356 | 2,120 | Upgrade
|
Net Income | -8,865 | 3,061 | 8,034 | 4,930 | 8,372 | 10,031 | Upgrade
|
Net Income to Common | -8,865 | 3,061 | 8,034 | 4,930 | 8,372 | 10,031 | Upgrade
|
Net Income Growth | - | -61.90% | 62.98% | -41.12% | -16.54% | 723.77% | Upgrade
|
Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 | 10 | Upgrade
|
Shares Outstanding (Diluted) | 15 | 17 | 15 | 15 | 15 | 10 | Upgrade
|
Shares Change (YoY) | -0.04% | 11.57% | 0.18% | -0.06% | 51.13% | 8.20% | Upgrade
|
EPS (Basic) | -590.49 | 203.88 | 535.00 | 327.00 | 555.00 | 1005.00 | Upgrade
|
EPS (Diluted) | -677.66 | 104.00 | 532.00 | 327.00 | 555.00 | 1005.00 | Upgrade
|
EPS Growth | - | -80.45% | 62.69% | -41.08% | -44.78% | 661.36% | Upgrade
|
Free Cash Flow | -20,059 | -16,237 | -14,137 | 3,699 | -4,843 | 10,487 | Upgrade
|
Free Cash Flow Per Share | -1336.15 | -963.66 | -936.13 | 245.38 | -321.05 | 1050.70 | Upgrade
|
Gross Margin | 54.17% | 58.84% | 63.71% | 62.42% | 63.84% | 63.36% | Upgrade
|
Operating Margin | -6.19% | 1.64% | 5.88% | 3.42% | 8.49% | 10.83% | Upgrade
|
Profit Margin | -4.96% | 1.64% | 4.79% | 3.52% | 6.71% | 8.66% | Upgrade
|
Free Cash Flow Margin | -11.22% | -8.68% | -8.43% | 2.64% | -3.88% | 9.06% | Upgrade
|
EBITDA | -5,039 | 7,844 | 12,977 | 7,400 | 12,629 | 14,251 | Upgrade
|
EBITDA Margin | -2.82% | 4.19% | 7.74% | 5.28% | 10.12% | 12.31% | Upgrade
|
D&A For EBITDA | 6,022 | 4,772 | 3,113 | 2,606 | 2,030 | 1,713 | Upgrade
|
EBIT | -11,061 | 3,073 | 9,864 | 4,794 | 10,599 | 12,538 | Upgrade
|
EBIT Margin | -6.19% | 1.64% | 5.88% | 3.42% | 8.49% | 10.83% | Upgrade
|
Effective Tax Rate | - | 11.93% | 4.25% | 12.05% | 13.94% | 17.45% | Upgrade
|
Advertising Expenses | - | 890.82 | 294.4 | 590.9 | 141.32 | 109.73 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.